Vaccine and Infectious Disease Division

2011 VIDD Publications

1. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS (London, England). 2011;25(5):691-700.

2. Aubert M, Ryu BY, Banks L, Rawlings DJ, Scharenberg AM, Jerome KR. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PloS one. 2011;6(2):e16825.

3. Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, et al. Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. The Journal of infectious diseases. 2011;204(10):1541-9.

4. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3(77):77ra29.

5. Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. The Journal of infectious diseases. 2011;203(1):117-21.

6. Balkus JE, Richardson BA, Mandaliya K, Kiarie J, Jaoko W, Ndinya-Achola JO, et al. Establishing and sustaining a healthy vaginal environment: analysis of data from a randomized trial of periodic presumptive treatment for vaginal infections. The Journal of infectious diseases. 2011;204(2):323-6.

7. Ballweber L, Robinson B, Kreger A, Fialkow M, Lentz G, McElrath MJ, et al. Vaginal Langerhans cells non-productively transporting HIV-1 mediate infection of T cells. Journal of virology. 2011;85(24):13443-7.

8. Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow RA, Fuchs J, et al. Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study). Journal of acquired immune deficiency syndromes (1999). 2011;57(3):238-44.

9. Barnabas RV, Webb EL, Weiss HA, Wasserheit JN. The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS (London, England). 2011;25(13):1559-73.

10. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011;29(32):5203-9.

11. Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, et al. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. The Journal of infectious diseases. 2011;204(10):1527-31.

12. Berger CT, Frahm N, Price DA, Mothe B, Ghebremichael M, Hartman KL, et al. High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control. Journal of virology. 2011;85(18):9334-45.

13. Bernabe-Ortiz A, Carcamo CP, Scott JD, Hughes JP, Garcia PJ, Holmes KK. HBV infection in relation to consistent condom use: a population-based study in Peru. PloS one. 2011;6(9):e24721.

14. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program. 2011;2011:305-9.

15. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. The Journal of clinical investigation. 2011;121(5):1673-80.

16. Boily M-C, Dimitrov DT, Abdool Karim SS, Masse B. The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. Sexually transmitted infections. 2011;87(7):646-53.

17. Boily M-C, Masse B, Dimitrov DT. Oral antiretroviral pre-exposure prophylaxis reduces the risk of HIV acquisition among men who have sex with men. Evid Based Med. 2011;16(5):146-7.

18. Bolton MJ, Garry RF. Sequence similarity between the erythrocyte binding domain of the Plasmodium vivax Duffy Binding Protein and the V3 loop of HIV-1 strain MN reveals a functional Heparin Binding Motif involved in binding to the Duffy Antigen Receptor for Chemokines. Virology journal. 2011;8(1):523.

19. Bolton MJ, Garry RF. Sequence similarity between the erythrocyte binding domain 1 of the Plasmodium vivax Duffy binding protein and the V3 loop of HIV-1 strain MN reveals binding residues for the Duffy Antigen Receptor for Chemokines. Virology journal. 2011;8:45.

20. Boudreault AA, Xie H, Leisenring WM, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(7):979-86.

21. Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis. 2011;13(3):244-9.

22. Butler-Wu SM, Burns EM, Pottinger PS, Magaret AS, Rakeman JL, Matsen FA, et al. Optimization of periprosthetic culture for diagnosis of Propionibacterium acnes prosthetic joint infection. J Clin Microbiol. 2011;49(7):2490-5.

23. Campbell MS, Mullins JI, Hughes JP, Celum C, Wong KG, Raugi DN, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PloS one. 2011;6(3):e16986.

24. Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med. 2011;62:157-70.

25. Cattamanchi A, Saracino M, Selke S, Huang M-L, Magaret AS, Celum C, et al. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. J Med Virol. 2011;83(10):1696-703.

26. Chao DL, Halloran ME, Longini IM. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci USA. 2011;108(17):7081-5.

27. Chao DL, Matrajt L, Basta NE, Sugimoto JD, Dean B, Bagwell DA, et al. Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States. Am J Epidemiol. 2011;173(10):1121-30.

28. Chapuis AG, Casper C, Kuntz S, Zhu J, Tjernlund A, Diem K, et al. HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood. 2011;117(20):5391-402.

29. Chen YQ, Zhang XC, Zhao LP. Estimating a Scale-change Effect for Time-varying Phenotypes in Genome-wide Association Studies Journal of Applied Statistical Science. 2011;18(4):31-46.

30. Choi RY, Fowke KR, Juno J, Lohman-Payne B, Oyugi JO, Brown ER, et al. C868T Single Nucleotide Polymorphism and HIV Type 1 Disease Progression Among Postpartum Women in Kenya. AIDS research and human retroviruses. 2011.

31. Choi S-M, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011;117(19):5050-6.

32. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PloS one. 2011;6(8):e21225.

33. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.

34. Corey L, Nabel GJ, Dieffenbach C, Gilbert PB, Haynes BF, Johnston M, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med. 2011;3(79):79ps13.

35. Cousins MM, Laeyendecker O, Beauchamp G, Brookmeyer R, Towler WI, Hudelson SE, et al. Use of a High Resolution Melting (HRM) Assay to Compare Gag, Pol, and Env Diversity in Adults with Different Stages of HIV Infection. PloS one. 2011;6(11):e27211.

36. Cramer RA, Rivera A, Hohl TM. Immune responses against Aspergillus fumigatus: what have we learned? Curr Opin Infect Dis. 2011;24(4):315-22.

37. Cui L, Gallagher LG, Ray RM, Li W, Gao D, Zhang Y, et al. Unexpected excessive chronic obstructive pulmonary disease mortality among female silk textile workers in Shanghai, China. Occup Environ Med. 2011;68(12):883-7.

38. Curlin ME, Cassis-Ghavami F, Magaret AS, Spies AG, Duerr A, Celum CL, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS (London, England). 2011;25(2):153-8.

39. De Rosa SC, Thomas EP, Bui J, Huang Y, DeCamp A, Morgan C, et al. HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable. Journal of immunology (Baltimore, Md : 1950). 2011;187(6):3391-401.

40. Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, et al. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PloS one. 2011;6(8):e23136.

41. Dimitrov DT, Boily M-C, Baggaley RF, Masse B. Modeling the gender-specific impact of vaginal microbicides on HIV transmission. J Theor Biol. 2011;288:9-20.

42. Dimitrov DT, Kojouharov HV. Dynamically consistent numerical methods for general productive–destructive systems. Journal of Difference Equations and Applications. 2011;17(12):1721 - 36.

43. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, et al. Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression. Nat Med. 2011;17(8):989-95.

44. Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, et al. Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial. The Journal of infectious diseases. 2011;204 (12):1918-26.

45. Farquhar C, Lohman-Payne B, Overbaugh J, Richardson BA, Mabuka J, Bosire R, et al. Breast Milk HIV-1 RNA Levels and Female Sex Are Associated With HIV-1-Specific CD8+ T-Cell Responses in HIV-1-Exposed, Uninfected Infants in Kenya. The Journal of infectious diseases. 2011;204(11):1806-10.

46. Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, et al. Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. The Journal of infectious diseases. 2011;203(6):773-9.

47. Ferrari G, Korber B, Goonetilleke N, Liu MKP, Turnbull EL, Salazar-Gonzalez JF, et al. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog. 2011;7(2):e1001273.

48. Fielding K, Koba A, Grant AD, Charalambous S, Day J, Spak C, et al. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. PloS one. 2011;6(10):e25571.

49. Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert PB, et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). The Journal of infectious diseases. 2011;203(6):765-72.

50. Fleming TR, Odem-Davis K, Rothmann MD, Li Shen Y. Some essential considerations in the design and conduct of non-inferiority trials. Clin Trials. 2011;8(4):432-9.

51. Fredricks DN. Molecular methods to describe the spectrum and dynamics of the vaginal microbiota. Anaerobe. 2011;17(4):191-5.

52. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh M, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52(4):e56-93.

53. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh M, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52(4):427-31.

54. Friedrich D, Jalbert E, Dinges WL, Sidney J, Sette A, Huang Y, et al. Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1. Journal of acquired immune deficiency syndromes (1999). 2011;58(3):248-52.

55. Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrobial agents and chemotherapy. 2011;55(6):2696-703.

56. Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis. 2011;24(4):295-301.

57. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. The Journal of infectious diseases. 2011;203(7):969-75.

58. Gilbert PB, Hudgens MG, Wolfson J. Commentary on "principal stratification - a goal or a tool?" by judea pearl. The international journal of biostatistics. 2011;7(1).

59. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, et al. Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections. PLoS Pathog. 2011;7(9):e1002209.

60. Grahl N, Puttikamonkul S, Macdonald JM, Gamcsik MP, Ngo LY, Hohl TM, et al. In vivo Hypoxia and a Fungal Alcohol Dehydrogenase Influence the Pathogenesis of Invasive Pulmonary Aspergillosis. PLoS Pathog. 2011;7(7):e1002145.

61. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. The Lancet infectious diseases. 2011;11(7):507-15.

62. Hansen JD, Vojtech LN, Laing KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol. 2011;35(9):886-97.

63. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, Zhao H, et al. Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. Journal of virology. 2011;85(15):7523-34.

64. Heugel J, Boeckh M, Huang M-L, Dierks B, Hackman RC, Fredricks DN, et al. Detection of adeno-associated virus viremia in hematopoietic cell transplant recipients. The Journal of infectious diseases. 2011;204(11):1746-9.

65. Huang Y, Ballinger DG, Dai JY, Peters U, Hinds DA, Cox DR, et al. Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome medicine. 2011;3(6):42.

66. Huang Y, Fong Y, Wei J, Feng Z. Borrowing Information across Populations in Estimating Positive and Negative Predictive Values. Journal of the Royal Statistical Society Series C, Applied statistics. 2011;60(5):633-53.

67. Huang Y, Gilbert PB. Comparing biomarkers as principal surrogate endpoints. Biometrics. 2011;67(4):1442-51.

68. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. The Journal of infectious diseases. 2011;203(10):1474-83.

69. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, et al. Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;317(21):6671-80.

70. Jacob ST, Baeten JM, Hughes JP, Peinado J, Wang J, Sanchez J, et al. A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav. 2011;15(5):897-904.

71. Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Ann Intern Med. 2011;154(4):253-9.

72. Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, et al. Strengthening the reporting of genetic risk prediction  studies (GRIPS): explanation and elaboration. Eur J Hum Genet. 2011;19(5):18 p preceding 494.

73. Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur J Epidemiol. 2011;26(4):313-37.

74. Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, et al. Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. J Clin Epidemiol. 2011;64(8):e1-e22.

75. Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. European journal of clinical investigation. 2011;41(9):1010-35.

76. Jerome KR, Diem K, Huang M-L, Selke S, Corey L, Buchwald D. Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome. Diagn Microbiol Infect Dis. 2011;71(1):66-71.

77. Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. The Journal of clinical investigation. 2011;121(12):4600-9.

78. Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, et al. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine. 2011;29(10):1948-58.

79. Kenah E, Chao DL, Matrajt L, Halloran ME, Longini IM. The global transmission and control of influenza. PloS one. 2011;6(5):e19515.

80. Kim HN, Scott J, Cent A, Cook L, Morrow RA, Richardson BA, et al. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. J Viral Hepat. 2011;18(10):e447-52.

81. Kingkeow D, McNicholl JM, Maneekarn N, Wongtrakul J, Taechareonkul S, Suriyanon V, et al. Frequencies of IL10 SNP genotypes by multiplex PCR-SSP and their association with viral load and CD4 counts in HIV-1-infected Thais. Asian Pac J Allergy Immunol. 2011;29(1):94-101.

82. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, et al. Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial. PloS one. 2011;6(9):e24517.

83. Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011;80(1-2):42-9.

84. Laing KJ, Hansen JD. Fish T cells: recent advances through genomics. Dev Comp Immunol. 2011;35(12):1282-95.

85. Lauzier S, Levesque P, Drolet M, Coyle D, Brisson J, Masse B, et al. Out-of-Pocket Costs for Accessing Adjuvant Radiotherapy Among Canadian Women With Breast Cancer. J Clin Oncol. 2011;29(30):4007-13.

86. Lemke CD, Graham JB, Geary SM, Zamba G, Lubaroff DM, Salem AK. Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. Mol Pharm. 2011;8(5):1652-61.

87. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim S-Y, et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med. 2011;3(81):81ra36.

88. Li F, Finnefrock AC, Dubey SA, Korber BTM, Szinger J, Cole S, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PloS one. 2011;6(6):e20479.

89. Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, et al. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011;18(7):506-12.

90. Lingappa JR, Petrovski S, Kahle E, Fellay J, Shianna K, McElrath MJ, et al. Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PloS one. 2011;6(12):e28632.

91. Liu Y, Li F, Liu Y, Hong K, Meng X, Chen J, et al. HIV fragment gag vaccine induces broader T cell response in mice. Vaccine. 2011;29(14):2582-9.

92. Liu Y, McNevin JP, Holte S, McElrath MJ, Mullins JI. Dynamics of viral evolution and CTL responses in HIV-1 infection. PloS one. 2011;6(1):e15639.

93. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151-69.

94. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151-69.

95. Marty FM, Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 2011;1(6):555-62.

96. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. The Lancet infectious diseases. 2011;11(4):284-92.

97. McElrath MJ. Standing guard at the mucosa. Immunity. 2011;34(2):146-8.

98. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS (London, England). 2011;25(8):1057-64.

99. Meroz D, Yoon S-W, Ducatez MF, Fabrizio TP, Webby RJ, Hertz T, et al. Putative amino acid determinants of the emergence of the 2009 influenza A (H1N1) virus in the human population. Proc Natl Acad Sci USA. 2011;108(33):13522-7.

100. Migueles SA, Rood JE, Berkley AM, Guo T, Mendoza D, Patamawenu A, et al. Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog. 2011;7(2):e1002002.

101. Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I, et al. Intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689-96.

102. Misono S, Sie KCY, Weiss NS, Huang M-L, Boeckh M, Norton SJ, et al. Congenital cytomegalovirus infection in pediatric hearing loss. Arch Otolaryngol Head Neck Surg. 2011;137(1):47-53.

103. Mugo NR, Med M, Heffron R, Donnell D, Wald A, Were EO, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS (London, England). 2011;25(15):1887-95.

104. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PloS one. 2011;6(10):e25828.

105. Munoz F, Englund J. Infant pertussis: is cocooning the answer? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;53(9):893-6.

106. Nakamae H, Storer BE, Sandmaier BM, Maloney DG, Davis C, Corey L, et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact ofrecipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica. 2011;96(12):1838-45.

107. Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, et al. Effects of Bacterial Vaginosis-Associated Bacteria and Sexual Intercourse on Vaginal Colonization With the Probiotic Lactobacillus crispatus CTV-05. Sexually transmitted diseases. 2011;38(11):1020-7.

108. Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, et al. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS research and human retroviruses. 2011;27(5):557-67.

109. Patterson J, Hitti J, Selke S, Huang M-L, Watts DH, Brown Z, et al. Genital HSV detection among HIV-1-infected pregnant women in labor. Infect Dis Obstet Gynecol. 2011;2011:157680.

110. Pepe MS, Janes H. Commentary: Reporting standards are needed for evaluations of risk reclassification. Int J Epidemiol. 2011;40(4):1106-8.

111. Pergam SA, Forsberg CW, Boeckh M, Maynard C, Limaye AP, Wald A, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13(1):15-23.

112. Phipps W, Saracino M, Magaret AS, Selke S, Remington M, Huang M-L, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. The Journal of infectious diseases. 2011;203(2):180-7.

113. Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PloS one. 2011;6(4):e18526.

114. Piwowar-Manning E, Fiamma A, Laeyendecker O, Kulich M, Donnell D, Szekeres G, et al. HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043). BMC Infect Dis. 2011;11:251.

115. Pollack M, Heugel J, Xie H, Leisenring WM, Storek J, Young J-A, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(5):664-73.

116. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A. 2011;79(8):603-12.

117. Posavad CM, Magaret AS, Zhao L, Mueller DE, Wald A, Corey L. Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2. Vaccine. 2011;29(40):7058-66.

118. Prlic M, Bevan MJ. Cutting Edge: {beta}-Catenin Is Dispensable for T Cell Effector Differentiation, Memory Formation, and Recall Responses. Journal of immunology (Baltimore, Md : 1950). 2011;187(4):1542-6.

119. Prlic M, Hohl TM. iNKTs Foil Fungi. Cell Host Microbe. 2011;10(5):421-2.

120. Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, et al. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood. 2011;117(24):6542-51.

121. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PloS one. 2011;6(2):e16819.

122. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, Boeckh M, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerging Infect Dis. 2011;17(4):653-60; quiz 765.

123. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24(4):333-43.

124. Renaud C, Kuypers J, Englund JA. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J Clin Virol. 2011;52(2):70-8.

125. Renaud C, Kuypers J, Ficken E, Cent A, Corey L, Englund JA. Introduction of a novel parechovirus RT-PCR clinical test in a regional medical center. J Clin Virol. 2011;51(1):50-3.

126. Rickerts V, Khot PD, Myerson D, Ko DL, Lambrecht E, Fredricks DN. Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in Formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis. 2011;11:202.

127. Rivera A, Hohl TM, Collins N, Leiner I, Gallegos A, Saijo S, et al. Dectin-1 diversifies Aspergillus fumigatus-specific T cell responses by inhibiting T helper type 1 CD4 T cell differentiation. J Exp Med. 2011;208(2):369-81.

128. Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17(3):366-71.

129. Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. Sexually transmitted infections. 2011;87(7):594-600.

130. Roxby AC, Drake AL, John-Stewart G, Brown ER, Matemo D, Otieno PA, et al. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PloS one. 2011;6(5):e19947.

131. Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ. 2011;342:d1617.

132. Sandlin MI, Johnston C, Bowe D, Saracino M, Schacker T, Shaughnessy M, et al. Clinician and Patient Recognition of Anogenital Herpes Disease in HIV Positive Men Who Have Sex With Men. Sexually transmitted diseases. 2011;38(9):833-6.

133. Schiffer JT, Magaret AS, Selke S, Corey L, Wald A. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. The Journal of antimicrobial chemotherapy. 2011;66(11):2593-600.

134. Schiffer JT, Scott J, Corey L. A siege of hepatitis: fighting a defiant virus. Nat Med. 2011;17(3):253-4.

135. Schiffer JT, Wald A, Selke S, Corey L, Magaret AS. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. The Journal of infectious diseases. 2011;204(4):554-61.

136. Scott J, Holte S, Urban T, Burgess C, Coppel E, Wang C, et al. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. The Journal of infectious diseases. 2011;204(3):419-25.

137. Scott ME, Wilson SS, Cosentino LA, Richardson BA, Moscicki A-B, Hillier SL, et al. Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine. 2011;56(2):430-4.

138. Shi C, Hohl TM, Leiner I, Equinda MJ, Fan X, Pamer EG. Ly6G+ Neutrophils Are Dispensable for Defense against Systemic Listeria monocytogenes Infection. Journal of immunology (Baltimore, Md : 1950). 2011;187(10):5293-8.

139. Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity. 2011;34(4):590-601.

140. Sista ND, Abdool Karim Q, Hinson K, Donnell D, Eshleman SH, Vermund SH. Experience in international clinical research: the HIV Prevention Trials Network. Clinical investigation. 2011;1(12):1609-18.

141. Sobieszczyk ME, Lingappa JR, McElrath MJ. Host genetic polymorphisms associated with innate immune factors and HIV-1. Current opinion in HIV and AIDS. 2011;6(5):427-34.

142. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. The Journal of infectious diseases. 2011;203(8):1165-73.

143. Spiegelman D, Logan R, Grove D. Regression Calibration with Heteroscedastic Error Variance. The International Journal of Biostatistics. 2011;7(1).

144. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52(10):1212-7.

145. Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, Maenza J, et al. Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection. PloS one. 2011;6(12):e28952.

146. Strachan E, Saracino M, Selke S, Magaret AS, Buchwald D, Wald A. The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women. Brain Behav Immun. 2011;25(7):1475-81.

147. Sugarman J, Corneli A, Donnell D, Liu TY, Rose S, Celentano D, et al. Are there adverse consequences of quizzing during informed consent for HIV research? J Med Ethics. 2011;37(11):693-7.

148. Sugimoto JD, Borse NN, Ta ML, Stockman LJ, Fischer GE, Yang Y, et al. The effect of age on transmission of 2009 pandemic influenza A (H1N1) in a camp and associated households. Epidemiology. 2011;22(2):180-7.

149. Tronstein E, Johnston C, Huang M-L, Selke S, Magaret AS, Warren T, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441-9.

150. Uberti JP, Agovi M-A, Tarima S, Haagenson M, Gandham S, Anasetti C, et al. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant. 2011;46(1):34-43.

151. Wald A, Koelle DM, Fife K, Warren T, Leclair K, Chicz RM, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine. 2011;29(47):8520-9.

152. Wang CC, Cook L, Tapia KA, Holte S, Krows M, Bagabag A, et al. Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. J Clin Virol. 2011;50(1):4-7.

153. Wang S, Goguen JD, Li F, Lu S. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine. 2011;29(39):6802-9.

154. Wang Y, Feng Z, Yang Y, Self SG, Gao Y, Longini IM, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011;22(6):781-92.

155. White R, Chileshe M, Dawson L, Donnell D, Hillier S, Morar N, et al. Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa. Clin Trials. 2011;8(1):103-11.

156. Yager JE, Kadiyala S, Weiser SD. HIV/AIDS, food supplementation and livelihood programs in Uganda: a way forward? PloS one. 2011;6(10):e26117.

157. Zerr DM, Fann JR, Breiger D, Boeckh M, Adler AL, Xie H, et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood. 2011;117(19):5243-9.

158. Zhang GL, Ansari HR, Bradley P, Cawley GC, Hertz T, Hu X, et al. Machine learning competition in immunology - Prediction of HLA class I binding peptides. Journal of immunological methods. 2011;374(1-2):1-4.

159. Zheng NN, McElrath MJ, Sow PS, Mesher A, Hawes SE, Stern J, et al. Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa. Journal of acquired immune deficiency syndromes (1999). 2011;57(2):92-100.